Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK-guided dosing of β-lactam antibiotics during CRRT in sepsis
ChiCTR2100053246Phase 4Not yet recruiting
- Sponsor
- Third Xiangya Hospital, Central South University
- Start
- Jan 2022
- Modality
- Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of meropenem, imipenem, piperacillin + tazobactam and cefoperazone + sulbactam in sepsis (4 arms), sponsored by Third Xiangya Hospital, Central South University. Primary endpoint: Drug concentration in plasma and CRRT effluent. Planned start Jan 2022; status: not yet recruiting.
02
Drugs
meropenemimipenempiperacillin + tazobactamcefoperazone + sulbactam
03
Conditions
sepsis
Beyond the preview
Go deeper on ChiCTR2100053246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100053246.